News by subject: TRI

LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare diseases,...

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney...

Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, La., Apr. 15-18,...

Research Solutions , a trusted partner providing cloud-based workflow solutions to accelerate research for R&D-driven organizations, today launches their new Clinical Trial Landscape software solution, making clinical trial information more...

Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of the ASBrS, Dr. Michael Berry, presents data and...

Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France,...

Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with...

Professor Julia Scarisbrick of University of Birmingham on Friday, April 12, 2024, presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSE: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with...

Fluence, a global leader in education, training, and certification for practitioners of psychedelic medicine, and Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of...

Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver....

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDEtm) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data...

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo.,...

TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to discuss the latest...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of...

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's anti-amyloid beta (A?) protofibril* antibody for the treatment...

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine-     Seventy percent of subjects achieved ?50% reduction in monthly...

Diverse and patient-focused data set comprises 17 abstracts including one oral presentationFeatures new data analyses for UCB's generalized myasthenia gravis (gMG) treatments, including post hoc and open-label extension results from the pivotal Phase...

Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events have been reported, and no patients have discontinued the trial. "This is an important milestone in our...

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave's RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminoxtm...

Kyverna Therapeutics, Inc. , a patient-centered, clinical-stage biopharmaceutical company focused on...

Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been successfully dosed with SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate,...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request...

Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced published results from MRS-TU-2019EXT, a six-month clinical trial of 139 men with low testosterone studying the...

ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of...

Invitae , a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine...

NICO Corporation, a pioneer and leader in minimally invasive parafascicular surgery (MIPS), today announced the entire results of the ENRICH (Early MiNimally-invasive Removal of ICH) trial have been published in the New England Journal of...

Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across...

Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health (NIH) for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and...

Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell carcinoma (laBCC) trial (NCT06344052). The study will evaluate SP-002, an...

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care...

Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine Systemtm Kit, were presented as a Late-Breaking Clinical Trial at the American...

More hope for successfully combating some of the deadliest cancers. Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval...

North American Partners in Anesthesia (NAPA), a nation's leading single-specialty provider of anesthesia and pain management, today announced its clinical and revenue cycle systems have earned certified status by HITRUST for information security....

Harmony Biosciences Holdings, Inc. today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the...

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer. In...

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on...

Johnson & Johnson today announced the planned presentation of new non-clinical studies underscoring the molecular properties of nipocalimab, an investigational fully human monoclonal antibody targeting the neonatal fragment crystallizable receptor...

Blueprint...

Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime/MRx) continues to publish award-winning and industry-leading research on a range of clinical topics impacting the health care and pharmacy benefit management industry. Thought leaders from...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary Diffuspheretm technology to optimize drug delivery for applications with significant unmet need, today announced that the...

Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead...

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , today announced that it will present results from pre-clinical studies in its irritable bowel syndrome...

LPCN 2401 treatment resulted in statistically significant body composition improvement in menIncreased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%Reduced android fat (AF) by 4.1% and increased bone mineral content (BMC) by...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting...

Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine....

RaySearch Laboratories AB (publ) announces that QST, National Institutes for Quantum Science and Technology in Chiba, Japan, has selected the treatment planning system RayStation®* for clinical use at the QST hospital. The order was received and...